Tuberculous Meningitis in Two-Year-Old Male Boy: Evidence of Recent Transmission from Mother to Baby

An deden Çocuğa Bulaşmanın Kanıtı Olarak Tüberküloz Menenjitli İki Yaşında Erkek Çocuk

Shital Patil1, Nilesh Nagargoje2, C. R. Choudhary3

Abstract

Tuberculous (TB) meningitis is the commonest infectious disease of central nervous system in pediatric and geriatric cases. Tuberculosis can be prevented in children by diagnosing and treating cases of active TB amongst adults, as pediatric cases always acquire it passively from household contact of adults suffering from TB as disease in adults is multibacillary. Although significant data is available for the prevention of childhood extra-pulmonary and disseminated TB, offering them Bacillus Calmette-Guerin (BCG) vaccination, it is still not routinely offered during vaccination. In this case report, a two-year child with a history of failure to thrive and constitutional symptoms diagnosed with disseminated extra-pulmonary TB presenting as TB meningitis with a history of contact with the mother suffering from active sputum positive pulmonary TB receiving anti-TB treatment. In conclusion, we recommend BCG vaccination to all newborns, and tuberculin skin testing and isoniazid prophylaxis to the contact of adults with sputum positive pulmonary TB cases in India.

Key words: Tuberculous meningitis, BCG Vaccination, isoniazid, tuberculin skin test, recent transmission, mother to child.

Özet


Anahtar Sözcükler: Tüberküloz menenjit, BCG aşısı, isoniyazid, tüberkülin deri testi, anneden çocuğa bulaşma.

1Department of Pulmonary Medicine, MIMSR Medical College, Latur, Maharashtra, India
2Department of Internal Medicine, Government Medical College, Latur, Maharashtra, India
3Department of Pulmonary Medicine, Dr. S.N. Medical College, Latur, Maharashtra, India


Correspondence (İletişim): Shital Patil, Department of Pulmonary Medicine, MIMSR Medical College, India
e-mail: dsxpatil1980@gmail.com
The World Health Organization (WHO) current estimates in 2015 are that one million children currently suffer from TB worldwide (<15 years), and that more than 136,000 die each year (1). Many people believe that these numbers underestimate the true extent of the problem (2). About 70 to 80% of children with TB have the disease in their lungs (pulmonary TB). The rest are affected by TB disease in other parts of their body (extra-pulmonary TB). In the high-burden TB setting, it has been reported that 15 to 20% of all TB cases are among children, whereas in the low-burden TB setting, it is estimated that 2 to 7% of all TB cases are among children (2).

Tuberculous meningitis is a common infectious disease of the central nervous system in developing countries. Early diagnosis and treatment with chemotherapy and active management of the complications are of utmost importance to prevent the irreversible neurological sequelae and death. Delay in diagnosis and in the start of effective treatment results in poor prognosis and sequel in up to 25% of cases (3).

CASE
A 2-year-old male referred to outdoor of pulmonary medicine department from pediatric department with history of fever, and failure to thrive since three months, and mother of child was on anti-TB treatment for three months. Overall physical examination revealed that child was malnourished with scanty hypopigmented hairs over the scalp and most important clinical sign increases the head circumference of the child with open wide anterior fontanel, and multiple enlarged non-tender, discrete subcentimeter cervical lymph nodes present bilaterally. Neurological examination of the child suggests delayed gross and fine motor signs development with few gross motor signs showing neuroregression. Neck rigidity was positive with Kernig’s sign positive. Additionally, plantar reflexes showed extensor response and deep tendon reflexes showed exaggerated response. Respiratory system examination findings are apparently normal.

The mother of the child was suffering from sputum positive pulmonary TB and is on supervised chemotherapy as per National guidelines containing four ATT (anti-TB) drugs Isoniazid, Rifampin, pyrazinamide and Ethambutol. She is having respiratory symptoms for four months before initiation of anti-TB treatment, means that baby was exposed to open TB case for four months before start of treatment. She had completed treatment when baby was 14 month old. Isoniazid prophylaxis to child irrespective of contact with sputum positive pulmonary TB case was not offered, and tuberculin skin test screening was not done.

Plain chest X-ray of mother before initiation of anti-TB treatment is at Figure 1. A sputum examination acid fast bacillus (AFB) of the mother before initiation of treatment was 3+. After two months of intensive phase of chemotherapy, sputum conversion occurred and sputum for AFB was negative. Sputum conversion remained after completion of ATT for six months as per national guidelines. Chest X-ray was not done after the completion of ATT, as radiological response is not analyzed routinely in supervised regimen, only bacteriological response is assessed. Chest X-ray of child is performed in indoor unit is at Figure 2. We performed gastric aspirate for AFB consecutively on five days and collected early morning overnight fasting sample collected with 10 mL of normal saline and assessed after centrifugation of sample. Acid fast bacilli were detected in sample.

Tuberculin skin testing was done with five TU (tuberculin unit) of PPD (purified-protein derivative) given intradermal over volar aspect of left forearm and results were observed after 48 hours after test. Tuberculin test was positive with induration of 14 mm.

We performed computed tomography of brain plain and with contrast (Figure 3 and 4) to look for signs of tuberculous meningitis and its complications. Figures 3 and 4 showing mild dilatation of ventricle system seen, i.e. mild hydrocephalous. Also note mild cortico-cerebral atrophy.
Tuberculous meningitis in two-year-old male boy: Evidence of recent transmission from mother to baby | Patil et al.

All these features suggestive of infective etiology and TB needs to be ruled out. We performed cerebrospinal fluid examination and results were observed as:
- Proteins- 110 gm%
- Glucose- 56 mg%
- Total nucleated cells- 428/mm³
- Differential cell count on smear- 90% lymphocytes and 10% neutrophils
- Gram staining and Ziehl-Neelsen staining were inconclusive
- ADA (adenosine deaminase level) in cerebrospinal fluid- 24 units/liter

Blood sugar level is 110 mg%. Complete blood counts were as follows:
- Hemoglobin 8.6 gm%, total white blood cells counts 6000/mm³, predominant lymphocytes on differential counts, platelets were 4.5 lacs.

The child was started on anti-TB treatment consisting of four anti-TB drugs Isoniazid, rifampin, pyrazinamide, and streptomycin on the day of admission as per body weight. No cerebral decongestants were required as anterior fontanel was open. In addition to anti-TB drugs, we started dexamethasone and continued it for four weeks in tapering dosages. No seizures or any neurodeficit was observed during hospitalization with complete tolerance and compliance to all three oral anti-TB drugs and one parenteral drug. We discharged child after 20 days of hospitalization with adequate weight gain and advice for compliance and adherence of ATT with high protein diet. We followed child for near complete response to chemotherapy. After four weeks steroids and streptomycin for 90 days discontinued and the rest three oral drugs were continued until six months. After 24 weeks, isoniazid and rifampin were continued until 12 months of initiation of treatment. Response to ATT is excellent with complete radiological clearance of dilated ventricles on CT brain and no residual neurological deficit clinically.

DISCUSSION
Tuberculous meningitis occurs mainly in developing countries where tuberculosis TB is more common and the
wider incidence of the human immunodeficiency virus (HIV) favors the onset of a great number of cases. Children are among the subjects who most frequently suffer from TBM due to their relative inability to contain primary mycobacterium tuberculosis infection in the lung (4). Tuberculous meningitis is a devastating disease with about 30% mortality in the most severe forms; moreover, 50% of survivors have neurological sequelae, despite apparently adequate administration of antibiotics (5).

Tuberculous meningitis develops in two steps. Mycobacterium tuberculosis bacilli enter the host by droplet inhalation. Localized infection escalates within the lungs with dissemination to the regional lymph nodes. In individuals who develop TB meningitis, bacilli seed to the meninges or brain parenchyma, resulting in the formation of small sub-pial or sub-ependymal foci of metastatic caseous lesions, termed Rich foci. The second step in the development of TBM is an increase in size of a Rich focus, until it ruptures into the subarachnoid space. The location of the expanding tubercle (i.e., Rich focus) determines the type of the central nervous system (CNS) involvement. Tubercles rupturing into the subarachnoid space cause meningitis (6).

Currently, more than two billion people (i.e., one third of the world’s population) are infected with TB, of which approximately 10% will develop clinical disease. The incidence of TB is related to the prevalence of TB in the community, and it is still the most common type of chronic CNS infection in developing countries (6).

Although early and rapid identification of TB meningitis is crucial for successful disease management, in most of the cases, diagnosis is significantly delayed. Initial signs and symptoms of disease are non-specific, and the suspicion of TBM usually arises only some days or weeks after the disease’s onset and is not different in children who have or have not been vaccinated with BCG. Fever, headache, anorexia, and vomiting characterize the prodromal of the disease in older children, whereas failure to thrive, poor appetite, vomiting, and sleep disturbances are more common in younger ones (7). Tuberculous meningitis is more easily suspected when these symptoms are associated with a history of recent contact with a case of documented TB.

Walker et al. (9) reported that BCG vaccination is partially protective against TB meningitis; therefore, a history of BCG vaccination or the presence of a BCG vaccination scar affords some degree of reassurance, when considering a diagnosis of TBM. In patients in whom TBM is suspected clinically, the diagnosis must be rigorously investi-
values between 4 and 8 U/L are insufficient to confirm or exclude the diagnosis of TB meningitis \( (p=0.07) \) (10). Similarly to clinical and laboratory findings, cerebral imaging can also contribute to diagnosing probable or possible TB meningitis. However, discrimination between TB meningitis and another cerebral disease is frequently very difficult. The most common brain CT or MRI features in children with TBM are hydrocephalus, which can be demonstrated in about 80% of cases, and basal meningeal enhancement, found in 75% of young patients. Infarction, as a result of ongoing vasculitis, particularly of the basal ganglia and of the areas of the medial striates and thalamo-perforating arteries and tuberculoma can be found in a smaller number of TBM pediatric cases. However, a combination of basal meningeal enhancement, infarction and hydrocephalus was found to have a high specificity for the diagnosis of TB meningitis, whereas basal meningeal enhancement was reported as the most sensitive feature (11).

The evidence of TB infection or disease outside the CNS can significantly increase the probability or possibility that a child with cerebral signs and symptoms can have TB meningitis. However, a great number of patients, particularly when HIV negative, will present with normal chest radiography or negative tuberculin skin testing (12). Moreover, particularly in high TB prevalence areas, a positive skin test with an unrelated illness has been frequently documented. Taking samples from sites of frequent TB infection such as lymph nodes, lung and gastric fluid can increase the likelihood of a positive culture. Gastric aspiration was positive in 68% of children with TBM (13).

Before the emergence of multidrug-resistant M. tuberculosis, three drugs were considered adequate for the first phase. More recently, to address the problem of resistance, four antibiotics for the initial months of treatment are preferred. However, there is no agreement on the duration of each of the two phases and on the total length of therapy. The intensive phase can range from two to six months and total treatment from six months to one year (14). For several years now, the drugs considered essential by the World Health Organization (WHO) to treat pulmonary TB in children are isoniazid (INH), rifampin (RMP), pyrazinamide (PZA), and ethambutol (EMB) (15).

World Health Organization regimen to treat Tuberculosis (15)
Isoniazid 10-15 mg/kg/24 h (max 300 mg) orally for 6 months
Rifampin 10-20 mg/kg/24 h (max 600 mg) orally for 6 months
Pyrazinamide 15-30 mg/kg/24 h (max 2 g) orally for 2 months
Streptomycin 20-40 mg/kg (max 1 g) intramuscular or intravenous for 2 months
Prednisone 2 mg/kg/24 h orally for 4 weeks, followed by a reducing course over 1-2 weeks.

In meningitis, most of the damage derives from the immune response elicited by the presence of bacterial pathogens in the CNS. This leads to a very relevant inflammatory process with significant infiltrative, proliferative and necrotizing vessel pathologies. The best steroid and the most effective scheme of administration are not known, as no data comparing different regimens are available currently. Moreover, data collected in children are few. According to the suggestions of the American and European Scientific Societies, it can be suggested the use of oral compounds for three or four weeks with subsequent reduction in few days (16,17).

Issues needs to be considered:
1. BCG Vaccination and role in preventing pediatric disseminated tuberculosis (6)

Following exposure to tubercle bacilli, it takes about 6 to 8 weeks for a primary complex to develop. Six to twelve months after the primary infection, tuberculous meningitis, secondary to hematogenous spread, may occur. The commonest age group for tuberculous meningitis is nine months to three year. BCG vaccination prevents hematogenous dissemination and development of TBM to the extent of 60-80%. Immunity following vaccination takes about eight to ten weeks to develop during which interval exposure to tubercle bacilli can cause disseminated infection. Hence BCG vaccination is must in all the newborns in high TB prevalence setting particularly in India (6).

2. Role of Tuberculin test (18)

The standard tuberculin test recommended for use is the Montoux’s test. Commercially available tuberculins in the country are one, two and five Tuberculin Unit (TU) PPD (RT23 equivalent). It is important to raise a wheal of about 6 mm after the intra-dermal injection and the test is read 48-72 hours after an injection. Ballpoint or palpatory methods are used to read the induration. The width of reaction (induration) in the horizontal plane is noted for interpretation. The Montoux’s test or PPD skin test is considered positive, if the duration is 10 mm or more. This cut-off was recommended using a 1 TU PPD RT23. Currently, the laboratories more often use 5 TU PPD (RT23 equivalent), or sometimes even some other higher

www.respircase.com
CONCLUSIONS 

Tuberculosis in a child represents recent and ongoing transmission of TB bacteria. Young children particularly below six years of age are most likely to become exposed and infected with TB by close contacts, such as family members. A high index of suspicion is thus required in evaluating these cases and all possible measures should be taken to confirm tuberculosis to have successful treatment. The outcome is excellent, compliance is adequate and with insignificant side effects in pediatric cases. Duration of treatment and treatment outcome is similar to adults. We recommend extended regimen for EPTB, i.e. up to 12 months in TB meningitis cases.

CONFLICTS OF INTEREST

None declared.

AUTHOR CONTRIBUTIONS


REFERENCES

2. “Childhood Tuberculosis Roadmap”, 11th November 2012. [CrossRef]


